Posizioni attive di Valerie Ceva
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
BioAegis Therapeutics, Inc.
 BioAegis Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology BioAegis Therapeutics, Inc. manufactures medicinal chemicals. It develops a portfolio of biomarker-directed treatments for a range of indications. The company was founded by Susan L. Levinson and is headquartered in North Brunswick, NJ. | Direttore/Membro del Consiglio | - | - |
| Direttore operativo | - | - | |
Azure Biotech, Inc.
 Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Direttore/Membro del Consiglio | 01/08/2013 | - |
| Segretario Aziendale | - | - |
Storia della carriera di Valerie Ceva
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| Director/Board Member | 2 |
| Chief Operating Officer | 1 |
| Corporate Secretary | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
BioAegis Therapeutics, Inc.
BioAegis Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology BioAegis Therapeutics, Inc. manufactures medicinal chemicals. It develops a portfolio of biomarker-directed treatments for a range of indications. The company was founded by Susan L. Levinson and is headquartered in North Brunswick, NJ. | Health Technology |
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |
- Borsa valori
- Insiders
- Valerie Ceva
- Esperienza
